Clinical Trial Update: Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis [Phase 3]

View source ↗

Summary

Phase 3 trial assessing adherence to GRAZAX grass pollen immunotherapy in seasonal allergic rhinitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Grass Pollen Allergy

Drugs mentioned

• GRAZAX (birch pollen sublingual immunotherapy tablet)

Snippet

Sponsor: ALK-Abelló A/S | Conditions: Allergic Rhinitis, Grass Allergy | Phase 3 | Status: COMPLETED